| Articore Group Limited (ATG) ORDINARY FULLY PAID |
Consumer Discretionary |
$78 |
Letter to Shareholders
|
28 Jul 2025 11:11AM |
$0.200 |
$0.265 |
risen by
32.50%
|
|
| Chariot Resources Ltd (CC9) ORDINARY FULLY PAID |
Materials |
$30 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Jul 2025 11:10AM |
$0.050 |
$0.145 |
risen by
190%
|
|
CC9 - Price-sensitive ASX Announcement
Full Release
Key Points
- Progress was made in lithium exploration at the Black Mountain, Resurgent, and Copper Mountain projects in the USA.
- Significant drilling activities were completed at the Black Mountain project, with ongoing sampling and permitting.
- The company successfully listed on the ASX following a completed IPO.
- Chariot Corporation Ltd remains well-funded, with sufficient cash to advance exploration activities.
- No mining production or development occurred during the December 2023 quarter.
- Financials and cash flow information are provided in the Appendix 5B Cash Flow Report.
- Updates were given regarding key board and executive appointments during the reporting period.
- Planned activities for the upcoming quarter include further exploration and project development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nova Eye Medical Limited (EYE) ORDINARY FULLY PAID |
Health Care |
$38 |
Investor Webinar Thursday 31 July @ 11.30 am AEST
|
28 Jul 2025 11:03AM |
$0.150 |
$0.133 |
fallen by
11.67%
|
|
| Xero Limited (XRO) ORDINARY FULLY PAID |
Information Technology |
$19,643 |
Application for quotation of securities - XRO
|
28 Jul 2025 11:03AM |
$179.650 |
$115.640 |
fallen by
35.63%
|
|
| Hydrocarbon Dynamics Limited (HCD) ORDINARY FULLY PAID |
Energy |
$4 |
Entitlement Offer Fully Underwritten
|
28 Jul 2025 10:58AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
| REA Group Ltd (REA) ORDINARY FULLY PAID |
Communication Services |
$24,057 |
REA Group 2025 AGM Date
|
28 Jul 2025 10:57AM |
$233.640 |
$182.090 |
fallen by
22.06%
|
|
| Stealth Group Holdings Ltd (SGI) ORDINARY FULLY PAID |
Industrials |
$200 |
iPhone 17 Pre-Sales Performance
|
28 Jul 2025 10:54AM |
$0.660 |
$1.340 |
risen by
103.03%
|
|
SGI - Price-sensitive ASX Announcement
Full Release
Key Points
- SGI is actively engaging in digital transformation to remain competitive.
- Recent financial performance reveals steady revenue growth, but profit margins are under pressure.
- The iPhone 17 pre-sales are expected to impact SGI’s distribution and retail channels positively.
- SGI is focusing on expanding its technology solutions and logistics divisions.
- Market challenges include increased competition and supply chain disruptions.
- Strategic partnerships and product diversification are central to SGI’s future growth plans.
- The outlook remains cautiously optimistic with a focus on operational efficiencies and leveraging new product launches.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sandon Capital Investments Limited (SNC) ORDINARY FULLY PAID |
Financials |
$128 |
SNC September Quarter Dividend Announcement
|
28 Jul 2025 10:51AM |
$0.850 |
$0.875 |
risen by
2.94%
|
|
SNC - Price-sensitive ASX Announcement
Full Release
Key Points
- Sandon Capital Investments Limited declared a fully franked interim dividend of 3.25 cents per share for the September quarter.
- Dividend payment date is scheduled for 27 October 2023.
- The record date for the dividend is 6 October 2023 and the ex-dividend date is 5 October 2023.
- A Dividend Reinvestment Plan (DRP) is available for shareholders, with an election deadline of 9 October 2023.
- Instructions for participation in the DRP are outlined, including eligibility and registration process.
- The announcement includes commentary on SNC’s portfolio performance and investment outlook.
- There is continued emphasis on active capital management and delivering value to shareholders.
- SNC reiterates its disciplined investment approach and commitment to transparency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ioneer Ltd (INR) ORDINARY FULLY PAID |
Materials |
$481 |
June 2025 - Quarterly Cash Flow Report
|
28 Jul 2025 10:47AM |
$0.125 |
$0.180 |
risen by
44%
|
|
INR - Price-sensitive ASX Announcement
Full Release
Key Points
- The report covers cash flows for the quarter ending June 2025.
- Significant focus on the Rhyolite Ridge Lithium-Boron Project and its development progress.
- Details operational, investing, and financing cash flows, with breakdowns of major items.
- Highlights cash used in operations and capital expenditures for project development.
- Outlines ongoing efforts to secure financing and manage working capital.
- Emphasizes prudent financial management and compliance with reporting obligations.
- Provides updates on key milestones achieved during the quarter.
- Maintains transparency regarding sources and uses of cash.
- Addresses forward-looking statements and associated risks.
- Ensures stakeholders are informed about the company’s financial and operational position as of June 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ioneer Ltd (INR) ORDINARY FULLY PAID |
Materials |
$481 |
June 2025 - Quarterly Activities Report
|
28 Jul 2025 10:47AM |
$0.125 |
$0.180 |
risen by
44%
|
|
INR - Price-sensitive ASX Announcement
Full Release
Key Points
- The report covers the company’s activities and developments for the June 2025 quarter.
- Advancements were made at the Rhyolite Ridge Lithium-Boron Project, including permitting and regulatory engagement.
- Progress in environmental management and continued collaboration with government authorities is highlighted.
- Discussions regarding project funding and strategic partnerships are ongoing.
- The company provides updates on resource and reserve estimates.
- Financial results for the quarter, including expenditures and cash position, are included.
- The report outlines key objectives and milestones planned for upcoming quarters.
- The document emphasizes the project’s role in the global lithium market and its strategic significance.
- Stakeholder and community engagement activities are discussed.
- Focus remains on maintaining regulatory compliance and advancing project development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Truscreen Group Limited (TRU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$10 |
Resignation of Director Juliet Hull
|
28 Jul 2025 10:45AM |
$0.016 |
$0.014 |
fallen by
12.50%
|
|
| Truscreen Group Limited (TRU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$10 |
Application for quotation of securities - TRU
|
28 Jul 2025 10:43AM |
$0.016 |
$0.014 |
fallen by
12.50%
|
|
| Lycopodium Limited (LYL) ORDINARY FULLY PAID |
Industrials |
$535 |
FY2025 Results Notification & Webinar
|
28 Jul 2025 10:41AM |
$11.680 |
$13.460 |
risen by
15.24%
|
|
| Truscreen Group Limited (TRU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$10 |
Corporate Action Notice
|
28 Jul 2025 10:41AM |
$0.016 |
$0.014 |
fallen by
12.50%
|
|
TRU - Price-sensitive ASX Announcement
Full Release
Key Points
- Truscreen Group Limited is announcing a pro rata non-renounceable rights issue to shareholders.
- Eligible shareholders can subscribe for 1 new share for every 5.4 shares held.
- The issue price is NZ$0.035 per new share.
- The company aims to raise approximately NZ$2.6 million before costs.
- Funds will be used for product development, commercialization, and working capital.
- The rights issue is partially underwritten.
- Key offer dates, including ex-date, record date, and offer closing, are specified in the notice.
- New shares will carry the same rights and obligations as existing shares.
- Eligibility is limited to shareholders in New Zealand and Australia as at the record date.
- The announcement fulfills disclosure requirements under NZX and ASX Listing Rules.
- No shareholder approval or prospectus is required for this rights issue.
- Director participation and underwriting arrangements are disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anatara Lifesciences Ltd (ANR) ORDINARY FULLY PAID |
Health Care |
$4 |
Anatara receives $969,455 in R&D Tax Incentive for FY25
|
28 Jul 2025 10:40AM |
$0.008 |
$0.014 |
risen by
75%
|
|
ANR - Price-sensitive ASX Announcement
Full Release
Key Points
- Anatara Lifesciences Ltd received $969,455 in R&D Tax Incentive funding for FY25.
- The funding comes from the Australian Federal Government’s R&D Tax Incentive program.
- Funds will support research and development efforts in both human and animal health portfolios.
- Projects supported include the GaRP human gastrointestinal health product and Detach® for animal health.
- The company is advancing its clinical and preclinical trial programs.
- The R&D Tax Incentive provides significant non-dilutive funding to Anatara.
- This funding will be used to progress product development and commercialization efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MA Credit Income Trust (MA1) ORDINARY UNITS FULLY PAID |
- |
$572 |
MA1 July 2025 Estimate Distribution Announcement
|
28 Jul 2025 10:36AM |
$2.050 |
$2.000 |
fallen by
2.44%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$91 |
Investor Presentation
|
28 Jul 2025 10:36AM |
$0.105 |
$0.076 |
fallen by
27.62%
|
|
| Titomic Limited (TTT) ORDINARY FULLY PAID |
Materials |
$330 |
TItomic Establishes UK Subsidiary
|
28 Jul 2025 10:33AM |
$0.285 |
$0.210 |
fallen by
26.32%
|
|
| Australian Rare Earths Limited (AR3) ORDINARY FULLY PAID |
Materials |
$41 |
Cleansing notice - Exercise of $0.10c Options
|
28 Jul 2025 10:33AM |
$0.130 |
$0.185 |
risen by
42.31%
|
|
| Saturn Metals Limited (STN) ORDINARY FULLY PAID |
Materials |
$271 |
Trading Halt
|
28 Jul 2025 10:32AM |
$0.415 |
$0.495 |
risen by
19.28%
|
|
STN - Price-sensitive ASX Announcement
Full Release
Key Points
- Saturn Metals Limited requested a trading halt on 28 September 2023.
- The trading halt is due to a pending announcement regarding a material capital raising.
- The halt will last until the earlier of a further announcement or the start of trading on 2 October 2023.
- The company states the halt is necessary to ensure an informed market and fair trading.
- No further details about the capital raising are disclosed in the announcement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Spartan Resources Limited (SPR) ORDINARY FULLY PAID |
Materials |
- |
Change in substantial holding for BNZ
|
28 Jul 2025 10:32AM |
$2.130 |
$2.130 |
fallen by
0%
|
|
| Benz Mining Corp (BNZ) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$340 |
Change in substantial holding from SPR
|
28 Jul 2025 10:32AM |
$0.590 |
$1.640 |
risen by
177.97%
|
|
| Australian Rare Earths Limited (AR3) ORDINARY FULLY PAID |
Materials |
$41 |
Application for quotation of securities - AR3
|
28 Jul 2025 10:29AM |
$0.130 |
$0.185 |
risen by
42.31%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$91 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Jul 2025 10:29AM |
$0.105 |
$0.076 |
fallen by
27.62%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report covers the period ending 31 March 2024.
- Arovella continued development of its ALA-101 and ALA-104 cell therapy programs targeting blood cancers.
- Progress made in manufacturing and preclinical development of ALA-101, including collaboration with clinical and manufacturing partners.
- ALA-104 program advanced with further research and development activities.
- New collaborations and licensing agreements established to expand the company's pipeline and capabilities.
- Ongoing regulatory and quality assurance activities to support progression toward clinical trials.
- Report includes Appendix 4C Cash Flow statement, outlining receipts from customers, research and development outflows, and overall financial position.
- Company maintains focus on capital management to fund its research and operational activities.
- No significant changes in business activities or control over entities during the quarter.
- The company is actively seeking additional funding sources to support continued operations and growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bowen Coking Coal Limited (BCB) ORDINARY FULLY PAID |
Materials |
$8 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Jul 2025 10:28AM |
$0.075 |
$0.075 |
fallen by
0%
|
|
Call 1300 880 160
Start a chat
Schedule a call
